Ord Minnett Biotechnology Conference Presentation
Released
Released
Announcement PDF
Fast-acting nasal
spray treatment for
erectile dysfunction
Corporate Presentation | 28 November 2024
Important notice
& Disclaimer
‣
Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd (Company) to provide general information about the Company. The information in this document is
in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has
taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation.
‣
Not an offer: this presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be
unlawful under the securities or other laws of that or any other jurisdiction.
‣
Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or
other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to
invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular
investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision.
‣
Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified
by such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”, "expects", "may", “intend”, "shall", "will", or "would". These statements are based on
information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to
risk factors associated with the Company’s business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable
but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in
such statements. There can be no assurance that actual outcomes will not differ materially from these statements.
‣
Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for
statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of
the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of
any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any
inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice.
‣
LTR Pharma Limited ACN 644 924 569
Corporate Presentation
2
Executive
Summary
Bringing to
market the first
nasal spray for ED
LTR Pharma is commercialising SPONTAN®
A ‘First in Class’ rapid, on-demand nasal spray treatment
for Erectile Dysfunction (ED)
Successful pivotal pharmacokinetic study
Demonstrated rapid onset and consistency of delivery
Disrupting the blockbuster PDE5 inhibitor market
Targeting to be the first PDE5 inhibitor nasal spray registered in
market estimated to reach US$6.0B in 2028
Clear commercial pathway
Expedited pathway to market – FDA 505(b)(2) pathway in the
US; Special Access in the Australian marketplace as an unmet
need
Additional nasal spray products planned for
development
Plan for additional SPONTAN products for ED, different
variations, price points and other indications in 2025
Corporate Presentation
3
Investment Highlights
LTR Pharma positioned in a clear gap in the market
Expedited
path to market
Compelling pivotal
pharmacokinetic
study data
Blockbuster
market with issues
Repurposed drugs with novel
delivery methods can reach the
market in the US and Australia
quickly
470% faster absorption than
oral tablets
Existing PDE5
inhibitors have a high
discontinuation rate due to
poor efficacy and side effects
Blue chip
partners
Aptar Pharma: Strategic Codevelopment partner - Nasdaq
listed;
Mayne Pharma: Commercial
manufacturing partner (CMO) ASX listed
Multiple upcoming
milestones
Expanding product portfolio
Manufacturing Scale up
Online Prescribing
Regulatory studies / meetings
Potential partnerships/licensing
Corporate Presentation
4
Market Problem
& Opportunity
Understanding
the Market Need
Physical causes
A significant healthcare
challenge affecting
relationships and
quality of life
‣ Heart Health
‣ Hormone Balance
‣ Diabetes
Psychological Impact
‣ Relationship problems
‣ Mental Wellbeing
‣ Day to day stress
‣ Medical Treatments
‣ Hair loss
‣ Weight loss
purchasing
50% Stop
PDE5 tablets
‣ Antidepressants
1
Of men over
60% 45 experience ED
2
Growing prevalence with
age impacts quality of life
Prevalence of ED with individuals with cardiovascular risk factors,
hypertension and diabetes, is reported as high as 50%
1) Carvalheira et al., "Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for
Discontinuation," Journal of Sexual Medicine, May 2012. 2) Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023
Corporate Presentation
6
Prevalence in key markets
As risk factors become more prevalent, so does ED
USA
China
Aus
EU
~30m
~33m
Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023
~150m
60.7%
of males 45y/o+
Presentation
7
Estimated Market size
Forecast to be US$6.0B market by 2028
$5.94B
US$6.0B
US$5.0B
US$ billions
US$4.0B
7.0% CAGR
$3.68B
US$3.0B
$2.58B
$2.76B
$2.95B
$3.38B
$3.16B
$3.61B
$3.87B
$4.15B
US$2.0B
US$1.0B
$1.11B
$1.18B
$1.27B
$1.36B
$1.45B
$1.56B
$1.67B
$1.79B
2021
2022
2023F
2024F
2025F
2026F
2027F
2028F
US$0.0B
US
ROW
Online sales expansion
Majority of ED medication is now sold through online channels
Corporate Presentation
8
Current treatments
Gold standard are PDE5 inhibitors which have several drawbacks
Phosphodiesterase-5 (PDE5)
inhibitors are first-line treatments
Issues with
PDE5 inhibitors
Product
Main
Brand(s)
Time before sexual
activity for dose
Approval
Date (US)
Generic
availability
Does not work
for 30-35% of patients
Sildenafil
Viagra
1 hour+
1998
Yes
Long response time of
1 hour + affects spontaneity
Tadalafil
Cialis
1 hour+
2003
Yes
Vardenafil
Levitra,
Staxyn
1 hour+
2003
Yes
Avanafil
Stendra
30 minutes+
2012
No
Adverse reactions
in up to 35% of
patients
= High discontinuation rate
Corporate Presentation
9
The search for a new branded option
Significant opportunity for branded assets
Opportunity to capture
market share at higher margins
Generics have grown to 700M* units annually
‣ ‘Rapid erosion of branded volume following patent expiries
‣ No product differentiation in a fragmented market
‣ Low margins for currently marketed generics
Branded drugs
‣ Commands significantly higher price points / margins
‣ Demonstrates pricing power and demand for premium brands
SPONTAN as a branded asset
‣ Market participants seeking new branded options to
differentiate in the marketplace
‣ Opportunity to capture market share through improved
therapy profile with higher margins than generics
Note: * 700M units claimed and does not include self-funded purchases
Corporate Presentation
10
Solution
Nasal Administration
Delivery mechanism can solve many
of issues facing PDE5 inhibitors
Advantages vs oral administration
More rapid
onset of action
Higher rate
of absorption
Lower adverse
reactions
Less active
pharmaceutical
ingredients required
Less drug degradation
due to bypassing the
digestive system
Corporate Presentation
12
SPONTAN® Pivotal Pharmacokinetic Study
Rapid onset effect, consistent
delivery and improved safety profile
‣ SPONTAN® nasal spray achieved rapid absorption and
faster onset of action compared to oral PDE5 inhibitors.
‣ SPONTAN® delivered similar bioavailability (Cmax) at half
the dose of oral PDE5 inhibitors.
‣
Significantly faster (Tmax) with SPONTAN® in as little
Parameter
Vardenafil
(5mg)
(10mg) oral
‣ Cmax (ng/ml).
‣ 13.0
‣ 16.7
‣ Tmax (min)
‣ 12 (range 9-15)
56 (Longest 150)
‣ Adverse Events
‣ 0
‣ 1
as 9 min (avg. 12 min) vs oral (56 min) - longest 2.5 hours.
‣ Confirmed safety and tolerability profile of SPONTAN®
vs oral dosing PDE5 Inhibitors.
‣ SPONTAN® demonstrated more consistent dosing than
oral PDE5 Inhibitors.
‣ Data to be used in regulatory filings in US, Australia
and other key markets.
Corporate Presentation
13
SPONTAN® The Fast-Acting Solution
Transforming ED treatment with speed and confidence
Speed Matters
Healthcare Professional Insight
Peak concentration in as little as
9 mins, 470% faster than oral tablets
Average onset: 12 mins vs 56 mins
Patients can respond in as little as 5 minutes,
well before peak concentration is reached *.
*Based on healthcare professional feedback
Less is More
Half the dose
Similar effectiveness
Better delivery consistency
Time to peak concentration
(minutes)
Tablets
Proven Safety
Validated safety profile
No severe events
Clinically proven
0
20
40
60
Corporate Presentation
14
Company
Overview
Company History
Progressed company substantially derisking the proposition
2020 - 2021
Acquired exclusive worldwide rights to
develop, manufacture and market SPONTAN®
through a licence agreement with SDS
Establishment of the
Scientific Advisory Board
in the field of Men’s Health
Validated the US FDA’s 505(b)(2)
regulatory pathway through an
expert regulatory review
2023
Developed the
protocol for its
bioequivalence
study, and gained
ethics approval
Initial Public Offer (IPO)
Completed an oversubscribed IPO.
Listed on the ASX on 11 December
2023 and raised AU $7M.
2022
Received early acceptance
from IP Australia for our
product trademark name
“SPONTAN®”
Adopted Mayne Health
as a commercial manufacturing
partner to produce SPONTAN® to
GMP standards
Optimised delivery and commercial
development of its nasal formulation
with drug stability data from nasal
spray device developer
2024
2020 Proof of
Concept trial
results published in
2023 in The Journal
of Sexual Medicine
Completed
packaging studies
for final commercial
product ahead of
bioequivalence study
and commercial sales
Conducted crucial
derisking activities
before moving into
clinical development
Study results released
SPONTAN®'s clinical study
to support regulatory filings,
enable early Australian
market access and
preparation for licensing and
partnering discussions
Australian Early
Access Scheme
commencement
Provision of
SPONTAN® for
unmet needs
Co-development
with Aptar Pharma
Partnership for the
commercialisation of
SPONTAN in the USA
and other key
markets
Online Platform
(Q1 CY25)
Increasing access
through telehealth
Corporate Presentation
16
Global Co-Development Agreement - Nasdaq listed
Aptar Pharma
Strategic partnership driving regulatory success and market readiness
Partnership Foundations
Regulatory & Development Activities
‣ Focuses on commercialisation in the US
and other key markets
Extractables & Leachables (E&L) studies
‣ Utilises Aptar's VP7 model nasal spray
technlogies
‣ Essential for regulatory submission
‣ Potential to develop additional next-gen
nasal spray products
Human Factors Study program
‣ Validating FDA compliance standards
‣ Evaluating user experience
Strategic Benefits
‣ Access to Aptar's comprehensive regulatory
services
‣ Optimising product usability
Regulatory Documentation
‣ Supports 505(b)(2) expedited pathway
‣ FDA-compliant instructional videos
‣ De-risks regulatory submissions
‣ Instructions For Use (IFU) development
‣ Foundation for future collaborations with global
leader in nasal spray products
‣ Supporting educational materials
Corporate Presentation
17
Clear path
to market
Expedited path to market
Seeking FDA and TGA approvals in the US & Australia and then other key markets
Milestones for FDA
FDA
(US)
Targeting a 505 (b)(2) approval
pathway regulatory strategy, on basis
it is “repurposing” of an existing
approved drug
Previous approval of oral tablet Vardenafil by
the FDA would allow inclusion of existing
safety and efficacy clinical and nonclinical
data
Preparation of regulatory documentation
E&L Studies (with Aptar)
Human Factors Studies (with Aptar)
Pre-IND submission meeting (Q1 CY 25)*
Animal Toxicology studies
New Drug Application (NDA)
TGA
(AUS)
Targeting Category 1 - Type F
Application process is expected to
be available to the Company
Given the existing safety profile of
Vardenafil, the regulatory pathways for
repurposed drugs allows for expedited
application
SPONTAN® is available to patients via the
TGA's SAS and APS for unmet needs
*FDA may require additional studies. To be confirmed after Pre-OND meeting
Milestones for TGA
Preparation of regulatory
documentation
Targeting pre submission meeting (Q2
CY 25)
Corporate Presentation
19
TGA Early Access Pathways
Building real-world evidence to support regulatory submissions
Current
Programs
Strategic
Value Drivers
Fast acting
Special Access Scheme (SAS)
Strategic Benefits
‣ (Individual patient access)
‣ Early patient access before full approvals
Authorised Prescriber Scheme (APS)
‣ Real-world data collection
‣ (Blanket approval per provider)
‣ Aids in future product education, product training
preparations, future variations to develop and
future product launches
Clinical Validation
Market Development
‣ Supporting regulatory submissions
‣ Building prescriber awareness before full approvals
‣ Strengthening partnership discussions
‣ Aids in greater market uptake post-approval*
‣ Building successful clinical patient profiles
‣ Foundation for digital/online access
Meeting
unmet needs
Growing
network
*Ref: Patil, S. (2024). PMC4763516. Early access programs: Benefits, challenges, and key considerations for successful impleme ntation.
Building online
prescribing
Q1 2025
Corporate Presentation
20
Commercialisation Pathways
Seeking FDA and TGA approvals in the US & Australia and other key markets
1
Australia’s TGA SAS
& APS early access
2
Partnering /
Licensing
3
Sales post
Regulatory Approval
‣ The successful clinical study results outlining the strong efficacy and safety profile enables
access in Australia through the TGA’s early access schemes, SAS and APS
‣ Early access schemes permit the supply of SPONTAN through healthcare professionals on a
compassionate use basis
‣ Exploration of partnership/licensing opportunities with significant global pharmaceutical
industry participants has begun
‣ LTR Pharma will advance these discussions in conjunction with progressing regulatory
approval pathways
‣ Targeting an expedited path to market in the US, Australia and other key markets
‣ Following regulatory approval, SPONTAN will be a new branded erectile dysfunction drug
leveraging online sales channels and partner networks
Corporate Presentation
21
Capturing the Digital Health Revolution
Building tomorrow's ED treatment platform today
Explosive Growth of telehealth
Strategic Position
US$140B+ market size by 2032*
Positioning SPONTAN for online access
Digital health revolution transforming patient care
telehealth integration and electronic prescribing
22% CAGR outpacing traditional healthcare*
Partner with other online prescribers in 2025
Commercial Pathway
Key Differentiators
Online Prescribing Q1 CY25
Specialist sexual health practitioners providing personalised care
Platform development – Q4 CY24
Comprehensive medical assessment, not just medications
Test rollout in Q1 CY25
Telehealth platform complementing established clinical expertise
Direct patient access through experts in ED
Privacy-focused patient solution
1st test market in Australia early 2025 – replicate success globally
* Source: Fortune Business Insights, Global Telehealth Market Report 2024-2032
Corporate Presentation
22
Corporate Overview
Strong Funding to Commercial Outcomes
(ASX:LTP) Public Market Overview (14 November 2024)
Share Price
A$1.36
52-week range
A$0.24 – A$2.15
Market Cap
A$209.17M
Cash equivalents (31 July 2024)
A$12.05M
Top 20 shareholder percentage
52.59%
1.
As at market close Thursday, 14 November 2024
Corporate Presentation
23
Contact
investors@ltrpharma.com
Authorised for release by the Board of Directors
www.ltrpharma.com
Share your feedback
Discover